SAGE-718 Ongoing Study Designs March 2022 DIMENSION Study - SAGE-718 Placebo-controlled study in patients with early Huntington's disease Status Enrolling Objectives • To evaluate the effect of SAGE-718 on cognitive performance in participants with HD • To evaluate the effect of SAGE-718 on daily function in participants with HD Indication Huntington's Disease Cognitive Impairment Primary Endpoint • Change from baseline in Composite score of the Huntington's Disease Cognitive Assessment Battery (HD-CAB) Pha ...